Literature DB >> 26201402

Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.

Valerie N Barton1, Nicholas C D'Amato1, Michael A Gordon1, Jessica L Christenson1, Anthony Elias1, Jennifer K Richer2.   

Abstract

Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) amplification. Due to the absence of these receptors, TNBC does not respond to traditional endocrine or HER2-targeted therapies that improve patient prognosis in other breast cancer subtypes. TNBC has a poor prognosis, and currently, there are no effective targeted therapies. Some TNBC tumors express androgen receptor (AR) and may benefit from AR-targeted therapies. Here, we review the literature on AR in TNBC and propose that TNBC be further sub-classified as either AR+ TNBC or quadruple negative breast cancer since targeting AR may represent a viable therapeutic option for a subset of TNBC.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26201402      PMCID： PMC6897499          DOI： 10.1007/s12672-015-0232-3

Source DB:  PubMed          Journal:  Horm Cancer        ISSN： 1868-8497            Impact factor:   3.869


  53 in total

1.  Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies.

Authors:  Semir Vranic; Zoran Gatalica; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-11       Impact factor: 2.967

2.  ARN-509: a novel antiandrogen for prostate cancer treatment.

Authors:  Nicola J Clegg; John Wongvipat; James D Joseph; Chris Tran; Samedy Ouk; Anna Dilhas; Yu Chen; Kate Grillot; Eric D Bischoff; Ling Cai; Anna Aparicio; Steven Dorow; Vivek Arora; Gang Shao; Jing Qian; Hong Zhao; Guangbin Yang; Chunyan Cao; John Sensintaffar; Teresa Wasielewska; Mark R Herbert; Celine Bonnefous; Beatrice Darimont; Howard I Scher; Peter Smith-Jones; Mark Klang; Nicholas D Smith; Elisa De Stanchina; Nian Wu; Ouathek Ouerfelli; Peter J Rix; Richard A Heyman; Michael E Jung; Charles L Sawyers; Jeffrey H Hager
Journal:  Cancer Res       Date:  2012-01-20       Impact factor: 12.701

3.  Identification of molecular apocrine breast tumours by microarray analysis.

Authors:  Pierre Farmer; Herve Bonnefoi; Veronique Becette; Michele Tubiana-Hulin; Pierre Fumoleau; Denis Larsimont; Gaetan Macgrogan; Jonas Bergh; David Cameron; Darlene Goldstein; Stephan Duss; Anne-Laure Nicoulaz; Cathrin Brisken; Maryse Fiche; Mauro Delorenzi; Richard Iggo
Journal:  Oncogene       Date:  2005-07-07       Impact factor: 9.867

4.  Expression of androgen receptors in triple negative breast carcinomas.

Authors:  Ivana Mrklić; Zenon Pogorelić; Vesna Capkun; Snježana Tomić
Journal:  Acta Histochem       Date:  2012-09-29       Impact factor: 2.479

5.  Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells.

Authors:  Tisheeka R Graham; Rami Yacoub; Latonia Taliaferro-Smith; Adeboye O Osunkoya; Valerie A Odero-Marah; Tongrui Liu; K Sean Kimbro; Dipali Sharma; Ruth M O'Regan
Journal:  Breast Cancer Res Treat       Date:  2009-11-18       Impact factor: 4.872

6.  Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?

Authors:  Damoun Safarpour; Shabnam Pakneshan; Fattaneh A Tavassoli
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

7.  Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.

Authors:  Aye Aye Thike; Luke Yong-Zheng Chong; Poh Yian Cheok; Hui Hua Li; George Wai-Cheong Yip; Boon Huat Bay; Gary Man-Kit Tse; Jabed Iqbal; Puay Hoon Tan
Journal:  Mod Pathol       Date:  2013-08-09       Impact factor: 7.842

Review 8.  Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

Authors:  Francisco E Vera-Badillo; Arnoud J Templeton; Paulo de Gouveia; Ivan Diaz-Padilla; Philippe L Bedard; Mustafa Al-Mubarak; Bostjan Seruga; Ian F Tannock; Alberto Ocana; Eitan Amir
Journal:  J Natl Cancer Inst       Date:  2013-11-22       Impact factor: 13.506

9.  Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Authors:  Dawn R Cochrane; Sebastián Bernales; Britta M Jacobsen; Diana M Cittelly; Erin N Howe; Nicholas C D'Amato; Nicole S Spoelstra; Susan M Edgerton; Annie Jean; Javier Guerrero; Francisco Gómez; Satyanarayana Medicherla; Iván E Alfaro; Emma McCullagh; Paul Jedlicka; Kathleen C Torkko; Ann D Thor; Anthony D Elias; Andrew A Protter; Jennifer K Richer
Journal:  Breast Cancer Res       Date:  2014-01-22       Impact factor: 6.466

10.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544
View more
  44 in total

Review 1.  Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Konstantinos Nikolettos; Dimitrios Dimitroulis; Evangelos Diamantis; Paraskevi Farmaki; Alexandros Patsouras; Errika Voutyritsa; Athanasios Syllaios; Constantinos G Zografos; Efstathios A Antoniou; Nikos Nikolettos; Alkiviadis Kostakis; Konstantinos Kontzoglou; Dimitrios Schizas; Afroditi Nonni
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 2.  Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Authors:  Nalo Hamilton; Diana Marquez-Garban; Vei H Mah; Yahya Elshimali; David Elashoff; Edward B Garon; Jaydutt Vadgama; Richard Pietras
Journal:  Crit Rev Oncog       Date:  2015

3.  Androgen Receptor Signalling Promotes a Luminal Phenotype in Mammary Epithelial Cells.

Authors:  Gerard A Tarulli; Geraldine Laven-Law; Mona Shehata; Kirsty A Walters; Iza M Denis; Md Mostafizur Rahman; David J Handelsman; Nicola R Dean; Wayne D Tilley; Theresa E Hickey
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-08-12       Impact factor: 2.673

Review 4.  Protein biomarkers for subtyping breast cancer and implications for future research.

Authors:  Claudius Mueller; Amanda Haymond; Justin B Davis; Alexa Williams; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2018-01-03       Impact factor: 3.940

Review 5.  Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.

Authors:  Guilhem Roubaud; Bobby C Liaw; William K Oh; David J Mulholland
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

6.  Race Disparities in the Contribution of miRNA Isoforms and tRNA-Derived Fragments to Triple-Negative Breast Cancer.

Authors:  Aristeidis G Telonis; Isidore Rigoutsos
Journal:  Cancer Res       Date:  2017-12-11       Impact factor: 12.701

7.  Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Authors:  Michael A Gordon; Nicholas C D'Amato; Haihua Gu; Beatrice Babbs; Julia Wulfkuhle; Emanuel F Petricoin; Isela Gallagher; Ting Dong; Kathleen Torkko; Bolin Liu; Anthony Elias; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2017-05-03       Impact factor: 6.261

8.  The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.

Authors:  Elizabeth A Wellberg; L Allyson Checkley; Erin D Giles; Stevi J Johnson; Robera Oljira; Reema Wahdan-Alaswad; Rebecca M Foright; Greg Dooley; Susan M Edgerton; Sonali Jindal; Ginger C Johnson; Jennifer K Richer; Peter Kabos; Ann D Thor; Pepper Schedin; Paul S MacLean; Steven M Anderson
Journal:  Horm Cancer       Date:  2017-07-24       Impact factor: 3.869

Review 9.  Steroid hormones, steroid receptors, and breast cancer stem cells.

Authors:  Jessica Finlay-Schultz; Carol A Sartorius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-08-12       Impact factor: 2.673

Review 10.  Endocrine resistance in breast cancer--An overview and update.

Authors:  Robert Clarke; John J Tyson; J Michael Dixon
Journal:  Mol Cell Endocrinol       Date:  2015-10-09       Impact factor: 4.102
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.